Breaking News Instant updates and real-time market news.

RGNX

Regenxbio

$21.70

0.65 (3.09%)

, DMTX

Acquired by RARE

08:03
08/25/17
08/25
08:03
08/25/17
08:03

Regenxbio to acquire Dimension Therapeutics for $3.41 per share in stock

REGENXBIO (RGNX) and Dimension Therapeutics (DMTX) announced that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction. Upon completion of the acquisition, REGENXBIO will add two lead product candidates to its pipeline: DTX301 for the treatment of ornithine transcarbamylase deficiency, which is designed to use the NAV AAV8 vector to deliver a copy of the OTC gene to liver cells. DTX301 is being evaluated under an active investigational new drug application for a Phase I/II clinical trial; and DTX401 for the treatment of glycogen storage disease type Ia, which is designed to use the NAV AAV8 vector to deliver a copy of the glucose 6-phosphatase gene to liver cells. An IND application is anticipated to be filed for DTX401 in early 2018. Both DTX301 and DTX401 have been granted Orphan Drug Designation in the United States and Europe. In addition, REGENXBIO will acquire DTX201 for the treatment of hemophilia A. DTX201 is designed to use REGENXBIO's NAV Technology to deliver a copy of the Factor VIII gene to liver cells, and is partnered through a global development and commercialization collaboration with Bayer. An IND application is anticipated to be filed for DTX201 in early 2018. Under the terms of the definitive agreement, Dimension will, following consummation of the acquisition, become a wholly owned subsidiary of REGENXBIO. In addition, Dimension shareholders will receive 0.1573 shares of REGENXBIO in exchange for each of their shares in Dimension and are expected to own approximately 10.9% percent of the combined entity. It is anticipated that the transaction will close by year-end 2017, subject to approval by Dimension shareholders, receipt of any required customary regulatory approvals and the satisfaction of other customary closing conditions. Morgan Stanley is serving as financial advisor and Covington & Burling LLP is serving as legal counsel to REGENXBIO. MTS Health Partners, L.P. is serving as financial advisor and Goodwin Procter LLP is serving as legal counsel to Dimension.

RGNX

Regenxbio

$21.70

0.65 (3.09%)

DMTX

Acquired by RARE

  • 11

    Sep

RGNX Regenxbio
$21.70

0.65 (3.09%)

03/21/17
03/21/17
NO CHANGE

REGENXBIO files to sell $75M in common stock
Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers. Chardan Capital Markets, LLC is acting as co-manager of the offering.
04/11/17
CHDN
04/11/17
NO CHANGE
Target $50
CHDN
Buy
REGENXBIO price target raised to $50 from $35 at Chardan
Chardan analyst Gbola Amusa raised his price target on REGENXBIO (RGNX) to $50 from $35, calling the company's appointment of Olivier Danos from Biogen (BIIB) as Chief Scientific Officer a "watershed moment" that increases his conviction in the company's long-term prospects. Amusa keeps a Buy rating on REGENXBIO shares.
08/16/17
EVER
08/16/17
INITIATION
Target $25
EVER
Outperform
Regenxbio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Regenxbio with an Outperform and a $25 price target.
DMTX Acquired by RARE

01/31/17
CANT
01/31/17
DOWNGRADE
Target $3
CANT
Neutral
Dimension Therapeutics downgraded to Neutral from Overweight at Cantor
Cantor Fitzgerald analyst Elemer Piros downgraded Dimension Therapeutics to Neutral and cut his price target for the shares to $3 from $32 saying the Phase 1/2 study in Hemophilia B highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. The stock is down 50% to $2.12 in midday trading.
05/12/17
SBSH
05/12/17
DOWNGRADE
Target $1.5
SBSH
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Dimension Therapeutics to Neutral after the company announced the discontinuation of its hemophilia B gene therapy program. The analyst says he's more cautious on the shares since a safety update on hemophilia B hasn't been disclosed since the program was discontinued. He cut his price target for the shares to $1.50 from $4.

TODAY'S FREE FLY STORIES

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

CTRV

ContraVir Pharmaceuticals

$0.25

-0.013 (-5.00%)

18:11
02/21/18
02/21
18:11
02/21/18
18:11
Hot Stocks
ContraVir Pharmaceuticals' hepatitis B treatment receives FDA Orphan designation »

ContraVir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:06
02/21/18
02/21
18:06
02/21/18
18:06
Earnings
AAC Holdings sees FY18 adjusted EPS 70c-75c, consensus 53c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:05
02/21/18
02/21
18:05
02/21/18
18:05
Earnings
AAC Holdings reports Q4 adjusted EPS 10c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DNKN

Dunkin' Brands

$60.70

-1.45 (-2.33%)

18:04
02/21/18
02/21
18:04
02/21/18
18:04
Hot Stocks
Baskin-Robbins expands in Toronto with plans for four new locations »

Baskin-Robbins, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.43

0.05 (0.05%)

18:01
02/21/18
02/21
18:01
02/21/18
18:01
Hot Stocks
Celanese to increase price of acetyl intermediate products »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

TUSK

Mammoth Energy

$20.04

-0.11 (-0.55%)

17:56
02/21/18
02/21
17:56
02/21/18
17:56
Earnings
Mammoth Energy reports Q4 EPS $1.48, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NSPR

InspireMD

$4.20

-0.26 (-5.83%)

17:53
02/21/18
02/21
17:53
02/21/18
17:53
Syndicate
Breaking Syndicate news story on InspireMD »

InspireMD files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$51.76

-0.25 (-0.48%)

17:52
02/21/18
02/21
17:52
02/21/18
17:52
Syndicate
Breaking Syndicate news story on E-Trade »

E-Trade files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$39.91

1.01 (2.60%)

17:47
02/21/18
02/21
17:47
02/21/18
17:47
Syndicate
Breaking Syndicate news story on Spirit Airlines »

Spirit Airlines files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAND

Bandwidth

$24.09

0.18 (0.75%)

, CAR

Avis Budget

$38.96

-0.98 (-2.45%)

17:42
02/21/18
02/21
17:42
02/21/18
17:42
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

BAND

Bandwidth

$24.09

0.18 (0.75%)

CAR

Avis Budget

$38.96

-0.98 (-2.45%)

MB

Mindbody

$33.35

-0.1 (-0.30%)

SAIL

SailPoint Technologies

$17.92

0.47 (2.69%)

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

GPOR

Gulfport Energy

$8.41

-0.32 (-3.67%)

SNPS

Synopsys

$88.46

-1.3 (-1.45%)

PE

Parsley Energy

$23.10

-0.19 (-0.82%)

P

Pandora

$4.87

-0.46 (-8.63%)

MLNX

Mellanox

ROKU

Roku

$51.10

-0.08 (-0.16%)

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

CSLT

Castlight Health

$3.85

0.3 (8.45%)

UCTT

Ultra Clean

$19.96

-0.4 (-1.96%)

TRN

Trinity Industries

$35.23

0.47 (1.35%)

RGR

Sturm, Ruger

$47.30

-1.05 (-2.17%)

CONE

CyrusOne

$48.81

-1.56 (-3.10%)

ADXS

Advaxis

$2.51

-0.08 (-3.09%)

GWPH

GW Pharmaceuticals

$132.33

1.5 (1.15%)

OMF

OneMain Holdings

$31.67

-0.22 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 11

    Mar

  • 13

    Mar

  • 14

    Mar

  • 21

    Mar

  • 26

    Mar

  • 28

    Mar

  • 29

    Mar

  • 03

    Apr

  • 15

    May

  • 23

    May

  • 27

    Jun

  • 22

    Feb

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:40
02/21/18
02/21
17:40
02/21/18
17:40
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:39
02/21/18
02/21
17:39
02/21/18
17:39
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$63.62

-0.75 (-1.17%)

17:32
02/21/18
02/21
17:32
02/21/18
17:32
Hot Stocks
Macquarie Infrastructure to reduce 2018 dividend to help fund asset repurposing »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.